Kratom Use, Synthetic Cannabinoids (K2), and Trends in the Drug Supply
Primary Care: Clinics in Office Practice · 2026-09 · 53 (3) · 431-439
DOI: 10.1016/j.pop.2026.03.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Primary Care: Clinics in Office Practice, 2026-09. Verfasst von Timothy J Kolosionek und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Toxicology, Department of Emergency and Hospital Medicine, Lehigh Valley Health Network, Emergency Medicine Research, 5th Floor, …. Hauptthemen laut MEDLINE: Cannabinoids, Mitragyna, Illicit Drugs. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Kratom and synthetic cannabinoids (SCs), often known as K2, are psychoactive substances gaining popularity, aided by a lack of regulation, despite serious health risks. Kratom is a plant-based substance containing mitragynine and 7-hydroxymitragynine, which cause opioid and stimulant effects. Users are at risk of opioid toxicity and withdrawal, as well as consequences of product contamination. SCs are cannabinoid receptor agonists despite a lack of structural similarity to cannabis. Adverse effects include increased rates of psychosis as well as seizures, stroke, and myocardial infarction, as well as dependent behaviors. SC regulation has limited effectiveness as new compounds often bypass existing policies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Toxicology, Department of Emergency and Hospital Medicine, Lehigh Valley Health Network, Emergency Medicine Research, 5th Floor, South Wing, 2545 Schoenersville Road, Bethlehem, PA 18017, USA. Electr…
- Division of Medical Toxicology, Department of Emergency and Hospital Medicine, Lehigh Valley Health Network, Emergency Medicine Research, 5th Floor, South Wing, 2545 Schoenersville Road, Bethlehem, PA 18017, USA.
Zitieren
APA
Kolosionek, T. J., & Amaducci, A. M. (2026). Kratom Use, Synthetic Cannabinoids (K2), and Trends in the Drug Supply. Primary Care: Clinics in Office Practice, 53(3), 431-439. https://doi.org/10.1016/j.pop.2026.03.004
Vancouver
Kolosionek TJ, Amaducci AM. Kratom Use, Synthetic Cannabinoids (K2), and Trends in the Drug Supply. Primary Care: Clinics in Office Practice. 2026;53(3):431-439. doi:10.1016/j.pop.2026.03.004
BibTeX
@article{Kolosionek2026,
author = {Kolosionek, Timothy J and Amaducci, Alexandra M},
title = {Kratom Use, Synthetic Cannabinoids (K2), and Trends in the Drug Supply},
journal = {Primary Care: Clinics in Office Practice},
year = {2026},
volume = {53},
number = {3},
pages = {431--439},
doi = {10.1016/j.pop.2026.03.004}
}
EUVIMED